Advancements in the study of IL-6 and its receptors in the pathogenesis of gout

IF 3.7 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Cytokine Pub Date : 2024-07-25 DOI:10.1016/j.cyto.2024.156705

Zeng Zhang , Peng Wang , Qin Xiong , Shanshan Xu , Dong Kang , Zhengguang He , Chengjiao Yao , Guilin Jian

{"title":"Advancements in the study of IL-6 and its receptors in the pathogenesis of gout","authors":"Zeng Zhang , Peng Wang , Qin Xiong , Shanshan Xu , Dong Kang , Zhengguang He , Chengjiao Yao , Guilin Jian","doi":"10.1016/j.cyto.2024.156705","DOIUrl":null,"url":null,"abstract":"<div><p>Gout is an autoinflammatory disease characterized by the deposition of monosodium urate crystals in or around the joints, primarily manifesting as inflammatory arthritis that recurs and resolves spontaneously. Interleukin-6 (IL-6) is a versatile cytokine with both anti-inflammatory and pro-inflammatory capabilities, linked to a variety of inflammatory diseases such as gouty arthritis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, and several types of cancer. The rapid production of IL-6 during infections and tissue damage aids in host defense. However, excessive synthesis of IL-6 and dysregulation of its receptor signaling (IL-6R) might contribute to the pathology of diseases. Recent advancements in clinical and basic research, along with developments in animal models, have established the significant role of IL-6 and its receptors in the pathogenesis of gout, although the precise mechanisms remain to be fully elucidated. This review discusses the role of IL-6 and its receptors in gout progression and examines contemporary research on modulating IL-6 and its signaling pathways for treatment. It aims to provide insights into the pathogenesis of gout and to advance the development of targeted therapies for gout-related inflammation.</p></div>","PeriodicalId":297,"journal":{"name":"Cytokine","volume":"182 ","pages":"Article 156705"},"PeriodicalIF":3.7000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cytokine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043466624002084","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Gout is an autoinflammatory disease characterized by the deposition of monosodium urate crystals in or around the joints, primarily manifesting as inflammatory arthritis that recurs and resolves spontaneously. Interleukin-6 (IL-6) is a versatile cytokine with both anti-inflammatory and pro-inflammatory capabilities, linked to a variety of inflammatory diseases such as gouty arthritis, rheumatoid arthritis, inflammatory bowel disease, vasculitis, and several types of cancer. The rapid production of IL-6 during infections and tissue damage aids in host defense. However, excessive synthesis of IL-6 and dysregulation of its receptor signaling (IL-6R) might contribute to the pathology of diseases. Recent advancements in clinical and basic research, along with developments in animal models, have established the significant role of IL-6 and its receptors in the pathogenesis of gout, although the precise mechanisms remain to be fully elucidated. This review discusses the role of IL-6 and its receptors in gout progression and examines contemporary research on modulating IL-6 and its signaling pathways for treatment. It aims to provide insights into the pathogenesis of gout and to advance the development of targeted therapies for gout-related inflammation.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

IL-6及其受体在痛风发病机制中的研究进展。

痛风是一种自身炎症性疾病，其特点是单钠尿酸盐结晶沉积在关节内或关节周围，主要表现为炎症性关节炎，可自行复发和缓解。白细胞介素-6（IL-6）是一种具有抗炎和促炎功能的多功能细胞因子，与痛风性关节炎、类风湿性关节炎、炎症性肠病、血管炎和几种癌症等多种炎症性疾病有关。在感染和组织受损时，IL-6 会迅速产生，帮助宿主进行防御。然而，IL-6 的过度合成及其受体信号转导（IL-6R）失调可能会导致疾病的病理变化。临床和基础研究的最新进展以及动物模型的发展已经证实了 IL-6 及其受体在痛风发病机制中的重要作用，但其确切机制仍有待全面阐明。本综述讨论了 IL-6 及其受体在痛风进展中的作用，并探讨了有关调节 IL-6 及其信号通路以进行治疗的当代研究。其目的是深入探讨痛风的发病机制，推动痛风相关炎症靶向疗法的开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cytokine 医学-免疫学

CiteScore

7.60

自引率

2.60%

发文量

262

审稿时长

48 days

期刊介绍： The journal Cytokine has an open access mirror journal Cytokine: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review. * Devoted exclusively to the study of the molecular biology, genetics, biochemistry, immunology, genome-wide association studies, pathobiology, diagnostic and clinical applications of all known interleukins, hematopoietic factors, growth factors, cytotoxins, interferons, new cytokines, and chemokines, Cytokine provides comprehensive coverage of cytokines and their mechanisms of actions, 12 times a year by publishing original high quality refereed scientific papers from prominent investigators in both the academic and industrial sectors. We will publish 3 major types of manuscripts: 1) Original manuscripts describing research results. 2) Basic and clinical reviews describing cytokine actions and regulation. 3) Short commentaries/perspectives on recently published aspects of cytokines, pathogenesis and clinical results.